| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.22600 |
| P698 | PubMed publication ID | 17530704 |
| P50 | author | Sebastian Schneeweiss | Q60162120 |
| Michael E Weinblatt | Q88922582 | ||
| Jeffrey N Katz | Q89419301 | ||
| Daniel H Solomon | Q91503755 | ||
| Jerry Avorn | Q6183214 | ||
| P2093 | author name string | Raisa Levin | |
| Paul E Sax | |||
| Soko Setoguchi | |||
| P433 | issue | 6 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1754-1764 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis | |
| P478 | volume | 56 |
| Q37343166 | "Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study". |
| Q44039298 | A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease |
| Q34154483 | Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission |
| Q37286386 | Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. |
| Q33765844 | Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. |
| Q35018415 | Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia |
| Q33819684 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry |
| Q41162030 | Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency |
| Q36934322 | Biologic agents in systemic vasculitis. |
| Q40484547 | Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q36943015 | Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study |
| Q33778719 | Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. |
| Q37814078 | Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis |
| Q33362177 | Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study |
| Q38540408 | Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations |
| Q36099620 | Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis |
| Q92723560 | Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age |
| Q26768270 | Elderly patients and inflammatory bowel disease |
| Q35062205 | Electronic medical records for discovery research in rheumatoid arthritis |
| Q34986307 | Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. |
| Q37187369 | Ethical issues in rheumatology clinical trials |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q37189376 | Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature |
| Q36033348 | Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis |
| Q92998078 | Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England |
| Q36574609 | Infection Risk and Safety of Corticosteroid Use. |
| Q37714705 | Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists |
| Q83647605 | Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor |
| Q34081364 | Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study |
| Q34019267 | Initiation of rheumatoid arthritis treatments and the risk of serious infections |
| Q36191250 | Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases |
| Q40298171 | Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study |
| Q37768157 | Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies |
| Q37643408 | Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. |
| Q38735146 | Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities |
| Q89458696 | Management of inflammatory rheumatic conditions in the elderly |
| Q99202798 | Managing rheumatoid arthritis during COVID-19 |
| Q34388159 | Necrotising fasciitis of the shoulder in association with rheumatoid arthritis treated with etanercept: a case report. |
| Q64266030 | Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease |
| Q37655598 | Obesity paradox, obesity orthodox, and the metabolic syndrome: An approach to unity |
| Q35134059 | Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease |
| Q49783699 | One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry |
| Q90362329 | Oral corticosteroid use during pregnancy and risk of preterm birth |
| Q37604968 | Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement |
| Q40355795 | Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty |
| Q53741447 | Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. |
| Q30425067 | RahU: an inducible and functionally pleiotropic protein in Pseudomonas aeruginosa modulates innate immunity and inflammation in host cells |
| Q38150731 | Rheumatoid arthritis in the elderly in the era of tight control |
| Q55025616 | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. |
| Q34153015 | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
| Q90665225 | Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study |
| Q35636624 | Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy |
| Q37330765 | Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. |
| Q36086443 | Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis |
| Q38827889 | Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance |
| Q35655534 | Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis |
| Q81382553 | Should infliximab be used to help maintain glucocorticosteroid-induced remission in patients with giant cell arteritis? |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q34792330 | TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis |
| Q28073436 | Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs |
| Q33704370 | The Clinical Usefulness of (18)F-FDG PET/CT in Patients with Systemic Autoimmune Disease |
| Q35617753 | The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses |
| Q34153010 | The delivery of evidence-based preventive care for older Americans with arthritis |
| Q38115131 | The influence of ageing on the development and management of rheumatoid arthritis |
| Q37715703 | The safety and side effects of monoclonal antibodies |
| Q35249608 | Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? |
| Q50154733 | Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease |
| Q37302417 | Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis |
| Q35161630 | Tumor necrosis factor blockade and the risk of viral infection |
| Q36806922 | Tumor necrosis factor inhibitors and infection complications |
| Q35812602 | Tumor necrosis factor-alpha deficiency impairs host defense against Streptococcus pneumoniae |
| Q48949308 | Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis |
| Q37580905 | Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety |
| Q84602740 | Update on Biologic Therapy in the Management of Axial Spondyloarthritis |
| Q37290628 | Update on the use of etanercept across a spectrum of rheumatoid disorders |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q36182373 | Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population |
| Q38701074 | Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
| Q82844774 | [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months] |
| Q83299548 | [Perioperative use of biologicals in rheumatoid arthritis] |
| Q83474742 | [Rheumatic patients in the intensive care unit] |
| Q81402998 | [Risk of infection by biologics] |
Search more.